Use of multibeam imaging sonar for observation of marine mammals and fish on a marine renewable energy site.

Environmental data is crucial for planning, permitting, execution and post construction monitoring of marine renewable energy projects. In harsh conditions in which marine renewable energy is harvested, integrated monitoring platforms comprising multibeam imaging sonar systems coupled with other sensors can provide multiparametric data of the marine environment surrounding marine renewable energy installations. The aim of this study was to test the possibilities of observing the occurrence of fish and marine mammals using a multibeam imaging sonar system deployed at a wave power test site.

Circulating Levels of the Cardiovascular Biomarkers ST2 and Adrenomedullin Predict Outcome within a Randomized Phase III Lung Cancer Trial (RASTEN).

Cardiovascular comorbidity is common in small cell lung cancer (SCLC) and may significantly affect treatment tolerability and patient outcome. Still, there are no established biomarkers for objective and dynamic assessment as a tool for improved treatment decisions. We have investigated circulating levels of midregional-pro-adrenomedullin (MR-proADM), midregional-pro-atrial-natriuretic peptide (MR-proANP), copeptin (surrogate for vasopressin) and suppression-of-tumorigenicity-2 (ST2), all known to correlate with various aspects of cardiovascular function, in a SCLC cohort (N = 252) from a randomized, controlled trial (RASTEN).

Colonisation of wave power foundations by mobile mega- and macrofauna - a 12 year study.

Environmental impacts from wave energy generators on the local mobile mega- and macrofauna community have been investigated in the Lysekil project by Uppsala University. Offshore renewable energy installations provide hard, artificial substrates, and as such, they could act as artificial reefs. Foundations with manufactured holes served as complex habitats and foundations without served as non-complex.

Palliative short-course hypofractionated radiotherapy followed by chemotherapy in esophageal adenocarcinoma: the phase II PALAESTRA trial.

The majority of patients with incurable esophageal adenocarcinoma suffer from dysphagia. We assessed a novel treatment strategy with initial short-course radiotherapy followed by chemotherapy with the primary aim to achieve long-term relief of dysphagia. This phase II trial included treatment-naîve patients with dysphagia due to esophageal adenocarcinoma not eligible for curative treatment.

Vasoactive peptides associate with treatment outcome ofbevacizumab-containing therapy in metastatic colorectal cancer.

Background: Hypertension is a common early adverse event of anti-angiogenic treatment of cancer and may associate with treatment response. However, blood pressure measurement as a surrogate response biomarker has methodological limitations, and predictive biomarkers of angiogenesis inhibitors are lacking. In disease associated with hypertension, vasoactive peptides have been linked to cardiovascular pressure load.

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.

For elderly patients with mantle cell lymphoma (MCL), there is no defined standard therapy. In this multicenter, open-label phase 1/2 trial, we evaluated the addition of lenalidomide (LEN) to rituximab-bendamustine (R-B) as first-line treatment for elderly patients with MCL. Patients >65 years with untreated MCL, stages II-IV were eligible for inclusion.